Individualized surgical treatment for patients with advanced-stage ovarian cancer: A contemporary approach

Experts Meeting on Gynecologic Oncology

May 19-21, 2016 San Antonio, USA

Samir A Farghaly

Cornell University, USA

Keynote: J Cancer Sci Ther

Abstract :

Worldwide, over 250,000 women are diagnosed with ovarian cancer each year, and about 140,000 women die from the disease. In the USA, estimated new cases are 21,290 and 14,180 deaths from ovarian cancer were recorded in 2015. The standard treatment of advanced ovarian cancer is cytoreductive surgery followed by a combination of platinum-based and taxane-based chemotherapy. The extent of residual disease following cytoreductive surgery correlates with response to adjuvant chemotherapy, rate of complete response at second-look assessment operations, and progression-free survival and overall survival. There is a correlation between the volume of residual disease and the oncologic outcome. Patients undergoing complete surgical resection noted to be having the optimum outcomes. The use of serum CA-125 levels, physical examination and CT imaging have shown to be lacking the accuracy in determining if disease can be optimally debulked. An individualized surgical approach for advanced stage ovarian cancer including ultra-radical debulking to 5 mm residual tumor revealed: Each decrease of 10% in residual tumor volume is followed by an increase of 5.5% in median survival in advanced ovarian cancer patients. Single port access robot assisted laparoscopic surgery is an ideal option. This surgical modality, results in faster recuperation following surgery, enables the early initiation of chemotherapy, improves quality of life (QOL) and an increase in the 5 year relative survival for those patients.

Biography :

Samir A Farghaly is a Physician/Scientist and national and international expert in Obstetrics and Gynecology at Joan and Sanford I. Weill College of Medicine and the New York Presbyterian Hospital/Weill Cornell Medical Center- Cornell University, New York, USA. He received his MD from London University and PhD degree in Molecular Biology from London University. He is the Founder and Editor-in Chief of Enliven: Challenges in Cancer Detection and Therapy Journal. He is serving as a Senior Editor/ Editor and member of editorial boards and editorial advisory boards of 18 international medical journals on gynecological cancers, gene expression & therapy, women’s health and gynecology. He has published 99 articles in reputed peer review journals. He has written several book chapters.

Email: samirfarghaly@yahoo.com